Portal de Periódicos da CAPES

Type II or type III radical hysterectomy compared to chemoradiotherapy as a primary intervention for stage IB2 cervical cancer

2018; Elsevier BV; Volume: 2018; Issue: 10 Linguagem: Inglês

10.1002/14651858.cd011478.pub2

1465-1858

Vivek Nama, Georgios Angelopoulos, Jeremy Twigg, John Murdoch, Jo Bailey, Theresa A Lawrie,

Endometriosis Research and Treatment

Cervical cancer is the fourth most common cancer in women, with 528,000 estimated new cases globally in 2012. A large majority (around 85%) of the disease burden occurs in low- and middle-income countries (LMICs), where it accounts for almost 12% of all female cancers. Treatment of stage IB2 cervical cancers, which sit between early and advanced disease, is controversial. Some centres prefer to treat these cancers by radical hysterectomy, with chemoradiotherapy reserved for those at high risk of recurrence. In the UK, we treat stage IB2 cervical cancers mainly with chemoradiotherapy, based on the rationale that a high percentage will have risk factors necessitating chemoradiotherapy postsurgery. There has been no systematic review to determine the best possible evidence in managing these cancers.